Cliniques Saint Luc

Research site

Belgium 10, av Hippocrate, 1200 Brussels, Belgium

2 trials recruiting
Hormone receptor positive HER2 negative breast cancer · Ischaemic stroke · Colon cancer
Adult patients

About Specializations

Cliniques Saint Luc in Brussels, Belgium specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Ischaemic stroke, Colon cancer, Neuroendocrine carcinoma of the skin, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

10, av Hippocrate1200 BrusselsBelgium

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 13

More sites in Brussels Belgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Alteplase
Sponsor:Insel Gruppe AG

Contact Research Centre

Colon cancer

Not recruiting

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo

France

Participants:65+ years
Substances:Capecitabine
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Neuroendocrine carcinoma of the skin+4

Not recruiting

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo

Study of BT-001 and Pembrolizumab for Patients with Advanced Solid Tumors, Including Sarcoma, Merkel Cell Carcinoma, Melanoma, Breast, and Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:BT-001
Sponsor:Transgene

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Unicancer

Contact Research Centre

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo

Belgium

Participants:65+ years
Substances:Cyclophosphamide
Sponsor:Unicancer

Contact Research Centre

Pneumonia

Not recruiting

Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

Investigational

Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Aon-D21
Sponsor:Aptarion Biotech AG

Contact Research Centre

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Unicancer

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites